BioTech Medics, Inc. (PINKSHEETS: BTMD)
announced today that it has received final test results from Retroscreen
Virology, at the University of London, Queen Mary’s School of Medicine,
London. BioTech had conducted an independent verifiable study to determine
the efficacy of virucidal SHBAN Solution against Avian HSN1 Influenza
NIBRG-14 Virus (also known as the Avian Bird Flu).
“We are very pleased to report the SHBAN Solution has clinically proven its
anti-viral properties and has topically killed the Avian Influenza virus.
But more significantly, SHBAN did so at such low concentrates that “there
was no cytotoxicity observed on the MDCK cell line after treatment,”
reported Keith Houser, CEO.
SHBAN is superior to most other anti-viral and anti-bacterial disinfectants
because SHBAN is 1) longer lasting, it does not evaporate within one minute
after application (as compared to alcohol); 2) it is non-toxic when used as
directed on humans and animals, 3) it is non-staining, non-bleaching and 4)
has no harmful or toxic odors. Most EPA approved disinfectant products in
the USA cannot make all of these claims.
BioTech plans on offering SHBAN Products that will include: SHBAN LIQUID
HAND SOAP & HAND SANITIZER additive. This is important to
hospitals/medical staff, migrant workers picking produce, food and
restaurant personnel, airlines staff/passengers, poultry farmers, plants
and plant workers. SHBAN Fogger Mist Solution is designed to cover large
areas such as cities and wild bird sanctuaries. It will be applied just
like mosquito fogger repellants. SHBAN Mister Solution will be sold to
sanitize poultry, poultry buildings and wildlife areas. The SHBAN spray
will be sprayed directly onto poultry or wild birds to cover them with an
invisible coating of SHBAN. Prior tests on bacteria have shown the SHBAN
solution to be effective up to 14 days. SHBAN Disinfectant will also be
sold for general cleaning purposes.
SHBAN is protected under US Letters of Patent #4,868,213, #5,514,808,
#5,574,050, #5,679,711 and #5,585,391 and several other foreign patents.
SHBAN is a trademark of BioTech Medics, Inc.
BioTech Medics welcomes government or world health official’s inquiries
should they desire to independently test the SHBAN solution.
The SHBAN(TM) solution, in previous in vitro and in vivo testing has been
evaluated for its antimicrobial properties against S. Aureus, S.
Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Baylor Medical
Center, Houston is a shareholder in the SHBAN Solution.
Safe Harbor: Forward-Looking Statements
This release contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 (the “Act”). “Conditional
expressions are intended to identify forward-looking statements within the
meaning of the Act and are subject to the safe harbor created by the Act.
Such statements are subject to certain risks, uncertainties and results
could differ materially from those expressed in the forward-looking
statements. The statements above have not been evaluated by the FDA. The
SHBAN product mentioned is not intended to diagnose, treat or cure any
disease.
Contact:
Keith Houser
CEO
Phone 972-274-5533
Information provided by: Findarticles.com
